Navigation Links
Anadys' Setrobuvir Named One of Windhover's Top 10 Most Interesting Infectious Disease Projects to Watch
Date:9/7/2011

SAN DIEGO, Sept. 7, 2011 /PRNewswire/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that setrobuvir (ANA598), the Company's direct-acting antiviral (DAA) currently in Phase IIb development for hepatitis C, has been selected as one of Windhover's Top 10 Most Interesting Infectious Disease Projects to Watch.

"We are honored to have setrobuvir identified as a Top 10 infectious disease project," said Kevin Eastwood, Anadys' Senior Vice President of Corporate Development.  "This recognition reflects the scarcity of later-stage development assets in hepatitis C and the strong desire on the part of companies to assemble combination regimens to treat this disease.  With a readout next month of the 12-week data from an ongoing Phase IIb trial, Anadys has positioned setrobuvir as a well-characterized agent, ideally suited to complement other DAAs as the treatment of HCV evolves to a DAA combination treatment paradigm."

Setrobuvir was selected by independent experts at Windhover Information and Herndon Company.  The selection criteria included the breadth of business development opportunities, the current size and growth of the targeted market, and the strength of science underlying the program.  Many assets selected in this manner by Windhover in prior years have been the focus of subsequent attractive business transactions.

As a selected company, Anadys will present at Windhover's 6th Annual Therapeutic Area Partnerships conference November 30-December 2, 2011 in Boston, MA.  Windhover is a leading provider of business information to senior executives in the pharmaceutical, biotechnology, and medical device industries.  

About setrobuvir in HCV

Setrobuvir, the Company's wholly-owned direct-acting antiviral or DAA, is an HCV RNA polymerase inhibitor that belongs to a chemical class referred to as non-nucleosides.  Setrobuvir has a well-characterized safety database in which more than 350 subjects have received the agent to date.  Anadys was granted U.S. Patent No. 7,939,524, which recognizes the Company's intellectual property rights to the composition of matter and methods of use for setrobuvir and related compounds. Setrobuvir has also received Fast Track Status from the FDA for the treatment of chronic hepatitis C or HCV.

Setrobuvir is currently in Phase IIb testing in combination with pegylated interferon and ribavirin for the treatment of HCV.  The primary endpoint of the study is Sustained Virological Response 24 weeks after patients complete treatment, known as SVR24.  All patients are scheduled to complete their 12 week visit by the end of the third quarter of 2011 and the Company expects to release preliminary 12 week data shortly thereafter.  Antiviral response data through 24 weeks are expected around year-end.  

In the second quarter this year, Anadys announced a cross-company clinical trial agreement with a large, commercial-stage biopharmaceutical company to study setrobuvir in combination with another DAA in healthy volunteers.

About Anadys

Anadys Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to improving patient care by developing novel medicines for the treatment of hepatitis C.  The Company believes hepatitis C represents a large unmet medical need in which meaningful improvements in treatment outcomes may be attainable with the introduction of new medicines.  Anadys is conducting a Phase IIb study of setrobuvir (ANA598), the Company's DAA, added to current standard of care for the treatment of hepatitis C.  The Company is  also developing ANA773, the Company's oral, small-molecule inducer of endogenous interferons that acts via the Toll like receptor 7, or TLR7, pathway in hepatitis C and plans to initiate a Phase IIa study shortly.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements."  Such statements include, but are not limited to, references to Anadys' expectations regarding data timelines from the setrobuvir Phase IIb study and its belief that setrobuvir is positioned as a well-characterized agent, ideally suited to complement other DAAs as the treatment of HCV evolves to a DAA combination treatment paradigm.  Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements.  For example, the results of preclinical and early clinical studies may not be predictive of future results, and Anadys cannot provide any assurances that setrobuvir or ANA773 will not have unforeseen safety issues, will have favorable results in ongoing or future clinical trials or will receive regulatory approval. In addition, Anadys' results may be affected by competition from other biotechnology and pharmaceutical companies, its effectiveness at managing its financial resources, its ability to enter into transactions around its product candidates, its ability to successfully develop and market products, difficulties or delays in its non-clinical studies or clinical trials, difficulties or delays in manufacturing its clinical trials materials, the scope and validity of patent protection for its products, regulatory developments and its ability to obtain additional funding to support its operations.  Risk factors that may cause actual results to differ are more fully discussed in Anadys' SEC filings, including Anadys' Form 10-Q for the quarter ended June 30, 2011.  All forward-looking statements are qualified in their entirety by this cautionary statement.  Anadys is providing this information as of this date and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.


'/>"/>
SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Anadys Announces Issuance of U.S. Patent Covering Setrobuvir (ANA598)
2. Anadys Pharmaceuticals Reports First Quarter 2011 Financial Results and Highlights
3. Anadys Pharmaceuticals Appoints Barry Labinger to Its Board of Directors
4. Anadys Pharmaceuticals to Present at the Cowen & Company Healthcare Conference
5. Anadys Pharmaceuticals to Report Fourth Quarter and Year-end 2010 Financial Results
6. Anadys Pharmaceuticals to Present at the Bio CEO & Investor Conference
7. Anadys Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference
8. Anadys Pharmaceuticals Initiates Phase IIb Study of ANA598 in HCV Patients
9. Anadys Pharmaceuticals Reports Third Quarter 2010 Financial Results and Highlights
10. Anadys Pharmaceuticals to Report Third Quarter 2010 Financial Results
11. Anadys Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... , Dec. 5, 2016 ... hydroxyurea (HU) in Complete Hematologic Response (CHR) ... ropeginterferon alfa-2b versus HU AOP will submit ... CONTINUATION-PV to obtain European marketing authorization in the coming months ... the FDA as it seeks approval for commercialization in the ...
(Date:12/4/2016)... 2016 Sickle cell disease (SCD) is an ... cells that get stuck in veins and block blood ... and complications leading to death. Each year, approximately 300,000 ... most of them lack access to comprehensive care or ... therapy for SCD, a pill called hydroxyurea approved more ...
(Date:12/2/2016)... SILVER SPRING, Md. , Dec. 2, 2016 /PRNewswire-USNewswire/ ... a new indication for Jardiance (empagliflozin) to reduce the ... 2 diabetes mellitus and cardiovascular disease. ... adults with type 2 diabetes mellitus," said Jean-Marc ... Metabolism and Endocrinology Products in FDA,s Center for Drug ...
Breaking Medicine Technology:
(Date:12/4/2016)... , ... December 04, 2016 , ... ... major cosmetic surgery can now take advantage of a cosmetic procedure known as ... rejuvenation treatment that reduces the appearance of age spots, fine lines, uneven ...
(Date:12/4/2016)... ... December 04, 2016 , ... Responsible dental care hinges ... brush properly to achieve optimal results. This important necessity inspired an inventor from Las ... a way to ensure that people break or avoid bad techniques of brushing the ...
(Date:12/2/2016)... ... ... Lori G. Cohen and Sara K. Thompson , shareholders in global ... Institute’s 21st Drug & Medical Device Litigation Conference , taking place in New York ... who chairs the firm’s Pharmaceutical, Medical Device & Health Care Litigation Practice and the ...
(Date:12/2/2016)... ... December 02, 2016 , ... On Dec. 2, 2016, CURE® magazine will host ... honoring the 2016 MPN Heroes—eight individuals who have made a difference in the field ... the standard of care, demonstrating leadership within the MPN community and/or a commitment to ...
(Date:12/2/2016)... Dothan, AL (PRWEB) , ... December 02, 2016 ... ... leaders from across the Dothan-Wiregrass Area in Alabama are expected to attend the ... Mike Schmitz, will help provide scholarship funds for area students and operating support ...
Breaking Medicine News(10 mins):